1. Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis
- Author
-
Valentina Donati, Javier Martin, Stefano Fiore, R. Vivarelli, Paolo Balestri, Francis Delpeyroux, Alessandro Plebani, Gabriele Buttinelli, Anna Rosa Soresina, Jill Marturano, Lucia Fiore, Laboratory of Virology, Istituto Superiore di Sanita [Rome], Department of Pediatrics, University of Brescia, Pediatrics Unit, University of Sienna, Epidémiologie Moléculaire des Entérovirus, Institut Pasteur [Paris], National Institute for Biological Standards and Control (NIBSC), Medicines and Healthcare Products Regulatory Agency (MHRA), Istituto Superiore di Sanità (ISS), and Institut Pasteur [Paris] (IP)
- Subjects
MESH: Sequence Analysis, DNA ,viruses ,MESH: Virulence ,medicine.disease_cause ,MESH: Variation (Genetics) ,Feces ,Mice ,chemistry.chemical_compound ,Agammaglobulinemia ,Paralysis ,MESH: Animals ,MESH: Capsid Proteins ,0303 health sciences ,Virulence ,Poliovirus ,MESH: Feces ,virus diseases ,MESH: Amino Acid Substitution ,3. Good health ,Poliomyelitis ,Child, Preschool ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,MESH: 5' Untranslated Regions ,medicine.symptom ,MESH: Poliovirus ,medicine.drug_class ,Molecular Sequence Data ,Reversion ,Biology ,Vaccines, Attenuated ,complex mixtures ,Virus ,Microbiology ,03 medical and health sciences ,Virology ,MESH: Vaccines, Attenuated ,medicine ,Animals ,Humans ,MESH: Agammaglobulinemia ,Viral shedding ,MESH: Mice ,030304 developmental biology ,MESH: Humans ,MESH: Molecular Sequence Data ,030306 microbiology ,MESH: Child, Preschool ,Genetic Variation ,Pleconaril ,Sequence Analysis, DNA ,medicine.disease ,Amino Acid Substitution ,MESH: Poliovirus Vaccine, Oral ,chemistry ,Poliovirus Vaccine, Oral ,MESH: Poliomyelitis ,Capsid Proteins ,Antiviral drug ,5' Untranslated Regions - Abstract
The molecular and antigenic properties of a Sabin-like type 2 poliovirus, isolated from the stool samples of a 2-year-old agammaglobulinaemic child who developed paralysis 1 year after receiving the third dose of oral poliovirus vaccine, were analysed. The virus revealed 0.88 % genome variation in the VP1 region compared with the standard reference strain, compatible with replication of the virus in the intestine over approximately 1 year. The typical mutations in the 5'NCR and VP1 associated with reversion to neurovirulence for Sabin type 2 poliovirus were found. Despite this, the virus was characterized by both PCR and ELISA tests as Sabin-like and showed temperature sensitivity and neurovirulence in transgenic mice typical of the Sabin type 2 vaccine strain. Gammaglobulin replacement therapy led rapidly to virus clearance, which, when combined with treatment with the antiviral drug pleconaril, stopped virus excretion; no further virus shedding occurred. This is the first case of poliomyelitis and long-term excretion from an immunodeficient patient to be reported in Italy through the active 'Acute Flaccid Paralysis' surveillance system.
- Published
- 2003
- Full Text
- View/download PDF